[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567346":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":14,"collaborators":7,"id":17,"slug":18,"hasResults":19,"nctId":20,"briefTitle":21,"officialTitle":21,"acronym":7,"eligibilityCriteria":22,"healthyVolunteers":19,"sex":23,"minAge":24,"maxAge":25,"enrollmentInfo":26,"targetDuration":7,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":7,"overallStatus":37,"whyStopped":7,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"Sichuan Provincial People's Hospital","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Lingai Pan","CONTACT","+8617708130236","panlingai2004@163.com",{"type":15,"investigatorFullName":10,"investigatorTitle":16,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Associate Clinical Professor","100567346","real-world-pharmacokineticpharmacodynamic-study-of-eravacycline-in-critically-iii-patients-100567346",false,"NCT06666998","Real-World Pharmacokinetic\u002FPharmacodynamic Study of Eravacycline in Critically III Patients","Inclusion Criteria:\n\n* Adult male or female aged 18-75 years\n* Not respond to initial empirical treatment, treatment time to reach Eravacycline steady-state concentration\n* Empirical antimicrobial treatment is ineffective\n* Eravacycline application for ≥ 3 days\n* Understand and sign informed consent\n\nExclusion Criteria:\n\n* Urinary tract infection\n* Allergic to Eravacycline, Tigecycline antibiotics or any excipients or have previously experienced serious adverse reactions\n* Any unstable or potentially endangering the safety of the subject and their compliance with the study as judged by the investigator; comorbidities or social circumstances that can make the subject unable to follow the study plan or even endanger the safety of the patient\n* Patients expected to survive for no longer than 48h.","ALL","18 Years","75 Years",{"count":27,"type":28},100,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the efficacy of Eravacycline in the treatment of patients with bacterial infection and to assess the pharmacokinetics of Eravacycline and to establish a population pharmacokinetic model of Eravacycline.",[32,33,34,35,36],"Eravacycline","Pharmacokinetics","Bacteria Infection","Bacterial Resistance to Antimicrobial","Empirical Antimicrobial Therapy","NOT_YET_RECRUITING","2024-11-01",{"date":40,"type":41},"2024-11-04","ACTUAL",{"date":38,"type":28},{"date":44,"type":28},"2026-11-01",{"name":5,"class":6}]